Media coverage about Senestech (NASDAQ:SNES) has trended positive on Thursday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Senestech earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2878474032413 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Senestech (NASDAQ:SNES) traded down 0.24% during mid-day trading on Thursday, hitting $4.15. The company had a trading volume of 16,585 shares. The firm has a 50-day moving average price of $5.61 and a 200 day moving average price of $7.34. The firm’s market capitalization is $42.39 million. Senestech has a 12 month low of $3.88 and a 12 month high of $10.69.
Senestech (NASDAQ:SNES) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.13. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.24 million. On average, equities research analysts forecast that Senestech will post ($1.10) earnings per share for the current fiscal year.
Several brokerages have recently weighed in on SNES. Zacks Investment Research downgraded Senestech from a “hold” rating to a “sell” rating in a research note on Thursday, June 1st. Roth Capital set a $14.00 price target on Senestech and gave the stock a “buy” rating in a research report on Saturday, May 13th.
In related news, CFO Thomas C. Chesterman sold 10,000 shares of Senestech stock in a transaction on Monday, June 12th. The stock was sold at an average price of $5.71, for a total transaction of $57,100.00. Following the completion of the transaction, the chief financial officer now directly owns 16,287 shares of the company’s stock, valued at $92,998.77. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 27.40% of the company’s stock.
Senestech Company Profile
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.